CytoSorbents

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytoSorbents reports growth in treatments and sales despite margin challenges

CytoSorbents demonstrated strong performance in treatment deliveries and sales momentum, despite margin challenges.
The company's focus on R&D and regulatory expertise positions it well for future growth opportunities.
Operational improvements and market expansion efforts are key to overcoming current challenges and driving profitability.
With a favorable competitive position and strategic initiatives, CytoSorbents aims to capitalize on emerging market opportunities.

CytoSorbents reports robust Q1 performance and eyes market expansion

CytoSorbents demonstrated strong performance in Q1 2023 with notable revenue and treatment milestones, alongside strategic market expansion efforts.
While facing challenges such as declining gross margins and managing costs, the company is focused on leveraging opportunities for growth and profitability.
Overall, CytoSorbents' financial health, product advancements, and market strategies position it well for future success and market expansion.

CytoSorbents reports robust Q2 earnings, eyes U.S. market expansion

CytoSorbents' Q2 2023 performance reflects strong revenue growth, operational milestones, and strategic partnerships driving future expansion.
While facing challenges in managing cash burn and regulatory hurdles, the company is well-positioned to capitalize on market opportunities.
With a focus on product innovation, market expansion, and financial sustainability, CytoSorbents aims to drive continued growth and market success.

CytoSorbents excels in Q3, eyes FDA approval and market expansion

CytoSorbents reported strong financial performance in Q3 2023, with revenue growth and a robust gross margin.
The company's focus on critical care markets and progress in the STAR-T trial indicate promising growth potential.
Challenges lie in maintaining cash reserves, securing FDA approvals, and navigating market competition.
Opportunities include expanding product portfolio, exploring capital sources, and leveraging favorable market conditions in Canada.

CytoSorb reports revenue growth and margin improvement in 2023

CytoSorb showed solid performance in 2023 with revenue growth and margin improvement.
Strategic partnerships and government support position the company for future growth.
Challenges include distributor order delays and market uncertainties in Germany.
Opportunities lie in new product initiatives, regulatory submissions, and international expansion.

CytoSorbents reports robust Q1 performance, eyes FDA submissions for growth

CytoSorbents delivered strong financial and operational performance in Q1 2024, driven by revenue growth and improved margins.
While facing challenges such as lower grant income and the need to maintain consistent performance, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial prudence, CytoSorbents aims to sustain its positive momentum throughout the year.

CytoSorbents reports revenue growth and operational improvements in Q2 2024

CytoSorbents' Q2 2024 showed positive revenue growth, operational improvements, and strategic advancements.
The company's focus on financial stability, regulatory progress, and cost efficiency bodes well for future performance.
While challenges like operational losses and regulatory hurdles persist, opportunities for growth and optimization are evident.
Overall, CytoSorbents is positioned for continued growth and success with a solid financial foundation and strategic direction.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2019 Results - Earnings Call Transcript

News for CytoSorbents Stock (CTSO)